LSE creators

Number of items: 11.
Health Policy
  • Gentilini, Arianna, Rana, Alina (2025). How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals. European Journal of Health Economics, 26(6), 945 - 968. https://doi.org/10.1007/s10198-024-01748-1 picture_as_pdf
  • Gentilini, Arianna, Neez, Emilie, Wong-Rieger, Durhane (2025). Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions. Value in Health, 28(5), 680 - 685. https://doi.org/10.1016/j.jval.2024.12.009 picture_as_pdf
  • Gentilini, Arianna, Kasonde, Lombe, Babar, Zaheer-Ud-Din (2025). Expanding access to NCD services via community retail pharmacies in LMICs: a systematic review of the literature. Journal of Pharmaceutical Policy and Practice, 18(1). https://doi.org/10.1080/20523211.2025.2462450 picture_as_pdf
  • Gentilini, Arianna, Parvanonva, Iva (2024). Managing experts’ conflicts of interest in the EU joint clinical assessment. BMJ Open, 14(11), e091777. https://doi.org/10.1136/bmjopen-2024-091777 picture_as_pdf
  • Gentilini, Arianna (2024). The role of patient organisations in innovation and access to medicines in Europe: evidence from rare and ultra-rare diseases [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.00004926 picture_as_pdf
  • Jenei, Kristina, Gentilini, Arianna, Haslam, Alyson, Prasad, Vinay (2024). Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. The Lancet Oncology, 25(8), 979 - 988. https://doi.org/10.1016/S1470-2045(24)00286-9 picture_as_pdf
  • Gentilini, Arianna, Miraldo, Marisa (2023). The role of patient organizations on research and development: evidence from rare diseases. Social Science & Medicine, 338, https://doi.org/10.1016/j.socscimed.2023.116332 picture_as_pdf
  • Gentilini, Arianna, Parvanova, Iva (2023). Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence. BMJ Open, 13(6). https://doi.org/10.1136/bmjopen-2022-071138 picture_as_pdf
  • Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan, Naci, Huseyin (2023). Safeguarding NICE from patient groups' conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243
  • Kamphuis, Bregtje, Fontrier, Anna-Maria, Haig, Madeleine, Politopoulou, Konstantina, Salyga, Hana, Gentilini, Arianna, Kanavos, Panos (2021). Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. LSE Consulting. picture_as_pdf
    • LSE
  • Gentilini, Arianna, Parvanova, Iva (2023). Industry funding of patient organisations in the United Kingdom: A retrospective study of commercial determinants, funding concentration and disease prevalence. [Dataset]. Dryad. https://doi.org/10.5061/dryad.fqz612jxd
  • Kamphuis, Bregtje, Fontrier, Anna-Maria, Haig, Madeleine, Politopoulou, Konstantina, Salyga, Hana, Gentilini, Arianna, Kanavos, Panos (2021). Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. LSE Consulting. picture_as_pdf
    • LSE Health
  • Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan, Naci, Huseyin (2023). Safeguarding NICE from patient groups' conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243